PT-141

FDA Approved

Bremelanotide

Also known as: Bremelanotide, Vyleesi

Moderate Risk

Sexual Health

A melanocortin receptor agonist that boosts sexual desire centrally in the brain. Unlike Viagra, PT-141 targets desire/arousal at the neurological level.

Benefits

Increases sexual desire and arousal

Works on brain pathways (MC3R/MC4R)

FDA-approved for HSDD in premenopausal women

Synergistic with PDE5 inhibitors for ED

Onset within 45 minutes (per FDA label)

Effective for psychological and physiological arousal

Side Effects & Risks

Nausea (40% of users)moderate

Flushing and facial rednessmild

Headachemild

Skin darkening with repeated usemoderate

Dosing Information

Typical Dose

1.75mg per dose

Administration

Subcutaneous injection

Cycle Length

As-needed, max once/24hrs, max 8 doses/month

Notes

Administer at least 45 min before activity (per FDA label). Off-label men's dose: 1-2mg.

Legal Status

FDA Status

FDA-APPROVED (Vyleesi for HSDD)

Availability

Prescription; also off-label through clinics

WADA Status

Banned by WADA (athletes beware)

Evidence

Evidence LevelHigh

FDA-approved with full clinical trial package. Extensive human data.